Zhang Zhaocun, Slater Richard C, Ferroni Matthew C, Kadow Brian T, Lyon Timothy D, Shen Bing, Xiao Zhiying, Wang Jicheng, Kang Audry, Roppolo James R, de Groat William C, Tai Changfeng
Department of Urology, Qilu Hospital, Shandong University, Jinan, P.R. China (Z.Z.); Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (Z.Z., R.C.S., M.C.F., B.K., T.D.L., B.S., Z.X., J.W., A.K., C.T.); Department of Urology, The Second Hospital, Shandong University, Jinan, P.R. China (Z.X.); and the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (J.R.R., W.C.D., C.T.).
Department of Urology, Qilu Hospital, Shandong University, Jinan, P.R. China (Z.Z.); Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (Z.Z., R.C.S., M.C.F., B.K., T.D.L., B.S., Z.X., J.W., A.K., C.T.); Department of Urology, The Second Hospital, Shandong University, Jinan, P.R. China (Z.X.); and the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (J.R.R., W.C.D., C.T.)
J Pharmacol Exp Ther. 2015 Nov;355(2):228-34. doi: 10.1124/jpet.115.226845. Epub 2015 Sep 9.
In α-chloralose anesthetized cats, we examined the role of opioid receptor (OR) subtypes (µ, κ, and δ) in tibial nerve stimulation (TNS)-induced inhibition of bladder overactivity elicited by intravesical infusion of 0.25% acetic acid (AA). The sensitivity of TNS inhibition to cumulative i.v. doses of selective OR antagonists (cyprodime for µ, nor-binaltorphimine for κ, or naltrindole for δ ORs) was tested. Naloxone (1 mg/kg, i.v., an antagonist for µ, κ, and δ ORs) was administered at the end of each experiment. AA caused bladder overactivity and significantly (P < 0.01) reduced bladder capacity to 21.1% ± 2.6% of the saline control. TNS at 2 or 4 times threshold (T) intensity for inducing toe movement significantly (P < 0.01) restored bladder capacity to 52.9% ± 3.6% or 57.4% ± 4.6% of control, respectively. Cyprodime (0.3-1.0 mg/kg) completely removed TNS inhibition without changing AA control capacity. Nor-binaltorphimine (3-10 mg/kg) also completely reversed TNS inhibition and significantly (P < 0.05) increased AA control capacity. Naltrindole (1-10 mg/kg) reduced (P < 0.05) TNS inhibition but significantly (P < 0.05) increased AA control capacity. Naloxone (1 mg/kg) had no effect in cyprodime pretreated cats, but it reversed the nor-binaltorphimine-induced increase in bladder capacity and eliminated the TNS inhibition remaining in naltrindole pretreated cats. These results indicate a major role of µ and κ ORs in TNS inhibition, whereas δ ORs play a minor role. Meanwhile, κ and δ ORs also have an excitatory role in irritation-induced bladder overactivity.
在α-氯醛糖麻醉的猫中,我们研究了阿片受体(OR)亚型(μ、κ和δ)在胫神经刺激(TNS)诱导的膀胱过度活动抑制中的作用,该抑制由膀胱内灌注0.25%乙酸(AA)引起。测试了TNS抑制对累积静脉注射选择性OR拮抗剂(μ受体用环丙二甲基吗啡、κ受体用去甲二氢吗啡酮、δ受体用纳曲吲哚)剂量的敏感性。在每个实验结束时给予纳洛酮(1 mg/kg,静脉注射,μ、κ和δ受体的拮抗剂)。AA引起膀胱过度活动,并显著(P < 0.01)将膀胱容量降低至生理盐水对照组的21.1%±2.6%。诱导脚趾运动的阈值(T)强度2倍或4倍的TNS显著(P < 0.01)将膀胱容量分别恢复至对照组的52.9%±3.6%或57.4%±4.6%。环丙二甲基吗啡(0.3 - 1.0 mg/kg)完全消除了TNS抑制,而不改变AA对照组的容量。去甲二氢吗啡酮(3 - 10 mg/kg)也完全逆转了TNS抑制,并显著(P < 0.05)增加了AA对照组的容量。纳曲吲哚(1 - 10 mg/kg)降低了(P < 0.05)TNS抑制,但显著(P < 0.05)增加了AA对照组的容量。纳洛酮(1 mg/kg)对环丙二甲基吗啡预处理的猫没有影响,但它逆转了去甲二氢吗啡酮引起的膀胱容量增加,并消除了纳曲吲哚预处理的猫中残留的TNS抑制。这些结果表明μ和κ受体在TNS抑制中起主要作用,而δ受体起次要作用。同时,κ和δ受体在刺激诱导的膀胱过度活动中也具有兴奋作用。